The Sema4 Story
Unlocking Answers to Your Health
More than a decade ago, the decoding of the human genome ushered in a new scientific era. This discovery paved the way for new developments in genomic research and medicine—yet, our understanding of the complexities of disease remains limited.
Introducing Sema4™—an innovative health information company dedicated to empowering healthier living through data.
Originating from the Mount Sinai Health System in New York City, Sema4 is an interdisciplinary partnership of scientists, doctors, engineers, clinicians, and genetic counselors. With a strong foundation of more than 160 years of clinical experience, world-class academic research, and pioneering information science, we are uniquely positioned to drive innovation in health.
We believe that the synthesis of information science and machine learning with the power of biodata at scale will revolutionize our ability to diagnose, treat, and prevent disease. At the center of our pursuit is a strong commitment to engaging patients as partners and sharing our data, so that every patient’s journey helps complete the greater picture.
Our name is derived from semaphore—a device used for sending signals. In this spirit, our team will discern signal from noise across trillions of data points in pursuit of our mission to gain meaningful insights into human health.
Sema4 Applies Data-Driven Approach to Expanded Carrier Screening, and Will Soon Utilize Exome Sequencing for Genetic Testing Powered by the Centrellis™ Health Intelligence Platform, Sema4’s Expanded Carrier Screen with Personalized Residual Risk Will Help Inform Pregnancy Planning Decisions.
Sema4 has landed its first outside investment, allowing it to continue its rapid growth. Sema4 updated its investors webpage to include five new entities: private equity behemoth Blackstone; venture capital funds Section 32, OakHC/FT, and Decheng Capital; and Connecticut Innovations, the state’s quasi-public investment agency.